Malignant external otitis: about 50 cases at Fann hospital center


  • Mame Sanou Diouf Department of ENT, HOGIP Hospital Center, Dakar, Senegal
  • Mouhamed Barry Department of ENT, HOGIP Hospital Center, Dakar, Senegal
  • Moustapha Ndiaye HALDDepartment of ENT, HOGIP Hospital Center, Dakar, Senegal
  • Abdourahmane Tall Department of ENT, Fann Hospital Center, Dakar, Senegal
  • Ciré Ndiaye Department of ENT, Fann Hospital Center, Dakar, Senegal
  • Malick Ndiaye Department of ENT, Fann Hospital Center, Dakar, Senegal
  • Fallou Niang Department of ENT, Fann Hospital Center, Dakar, Senegal
  • Cheikh Diène Niang Department of ENT, Fann Hospital Center, Dakar, Senegal
  • Faty Fall Department of ENT, HOGIP Hospital Center, Dakar, Senegal



Malignant otitis, Diabetes, Extrenal ear


Background: Malignant external otitis (MEO) is an osteitis of the skull base, originating in the external auditory canal. It is most common in elderly and diabetic patients. Early management prevents complications. The objective of the study is to provide an epidemiological, clinical, paraclinical, therapeutic and evolutionary profile.

Methods: From January 2010 to January 2021, we carried out a retrospective study in the ENT department of Fann hospital, selecting the patients hospitalized and suffering from malignant external otitis

Results: Fifty patients were included in this study. The mean age was 65, with a sex ratio (M/F) of 1.5. Forty-six patients were diabetic; 2 patients had leukemia and 2 had no previous history. The average length of hospital stay was 3 months. The reasons for consultation were otalgia, otorrhea and deafness in 96%, 80% and 32% respectively. Examination revealed otorrhea in 58%, peripheral facial paralysis in 54% and a polyp in 80%. Ear swab analysis isolated Pseudomonas aeruginosa in 28%. CT scan showed ear cavity filling in 40 cases and bone lysis in 26. Antibiotic treatment was based on ciprofloxacin or ofloxacin in 44% of cases, and the combination of ceftriaxone-ciprofloxacin or ofloxacin in 44%. The average duration of treatment was 3 months. There were 12% recurrences and 2 cases of death after an average follow-up of 10 months.

Conclusions: MEO is a rare pathology that occurs more frequently in elderly subjects with immunodepressive backgrounds. Antibiotic therapy has proved effective in treating this condition.


Bonfils P, Laccorreye O, Couloigner V. Le livre de l’interne; ORL. 2nd ed. France: Lavoisier Médecine sciences; 2014.

Bathokedeou A, Essobozou P, Akouda P, Essohanam B, Eyawelohn K. Epidemiological, clinical and therapeutic aspects of otitis externa: about 801 cases. Pan Afr Med J. 2014;17:142.

Bruno G, Valentina KM, Santoro R, Cammaroto G, Galletti F, Cascio A. Malignant external otitis. A case series from an Italian Tertiary-Care Hospital. Acta Med Mediter. 2014;30(6):1317-23.

Nawas MT, Daruwalla VJ, Spirer D, Micco GA, Alan G, Nemeth AJ. Complicated necrotizing otitis externa. Am J Otolaryngol Head Neck Med Surg. 2013;34: 706-9.

Rubin GJ, Branstetter BF, Yu VL. The changing face of malignant (necrotising) external otitis: clinical, radiological, and anatomic correlations. Lancet Infect Dis. 2004;4(1):34-9.

Chandler JR. Malignant external otitis. Laryngoscope. 1968;78(8):1257-94.

Sellem A, Cherif H, Ajmi W, Ben MR, Zgolli S, Akkari K, et al. Place des explorations isotopiques dans les otites externes nécrosantes. Méd Nucl. 2012; 45(1):40-5.

Gassab E, Krifa N, Sayah N, Khaireddine N, Koubaa J, Gassab A. L’otite externe nécrosante progressive: à propos de 36 cas. Latunisie Med. 2011;89(2):151-6.

Abdeljelil M, Kooli I, Marrakchi W, Aouam A, Loussaief C, Toumi A, et al. Otite externe nécrosante chez le diabétique: aspects cliniques, thérapeutiques et évolutifs. Ann Endocrinol. 2020;81(4):4266.

Long DA, Koyfman A, Long B. An emergency medicine-focused review of malignant otitis externa. Am J Emerg Med. 2020;38(8):1671-8.

Rubin J, Yu VL, Stool SE. Malignant external otitis in children. J Pediatr. 1998;113(6):965-70.

Treviño GJL, Reyes SLL, Hernández de LJE. Malignant otitis externa: An updated review. Am J Otolaryngol. 2021;42(2):102894.

Mahdyoun P, Pulcini C, Raffaelli C. Necrotizing otitis externa: a systematic review. Otol Neurotol. 2013; 34(4):620-9.

Martel J, Guyo TM, Darrouzet V. Otites externes "malignes" ou nécrosantes progressives. Revue Lacomen. 1999;5(4):405-15.

Salit IE, Miller B, Wigmore M, Smith JA. Bacterial flora of the external canal in diabetics and non-diabetics. Laryngoscope. 1982;92(6):672-3.

Hobson CE, Moy JD, Byers KE, et al. Malignant otitis externa: evolving pathogens and implications for diagnosis and treatment. Otolaryngol Head Neck Surg. 2014;151(1):112-6.

Jacobsen LM, Antonelli PJ. Errors in the diagnosis and management of necrotizing otitis externa. Otolaryngol Head Neck Surg. 2010;143:506-9.

Lee SK, Lee SA, Seon SW. Analysis of prognostic factors in malignant external otitis. Clin Exp Otorhinolaryngol. 2017;10(3):228-35.

Halwani C, Zoghlami I, Zgolli C, Harhira R, Akkari K, Ben Mhamed R, et al. Les otites externes nécrosantes fongiques chez le diabétique. Ann Endocrinol. 2017;78(4):420-1.

Nadol JB. Histopathology of pseudomonas osteomyelitis of the temporal bones starting as malignant external otitis. Am J Otolaryngol. 198;1: 359-71.

Glikson E, Sagiv D, Wolf M, Shapira Y. Necrotizing otitis externa: diagnosis, treatment, and outcome in a case series. Diagn Microbiol Infect Dis. 2017;87(1): 74-8.

Levenson JM, Parisier SC, Dolitsky J, Bindra G. Ciprofloxacin: drug of choice in the treatment of malignant external otitis (MEO). Laryngoscope. 1991; 101:821-4.

Berenholz L, Katzenell U, Harell M. Evolving resistant pseudomonas to ciprofloxacin in malignant otitis externa. Laryngoscope. 2002;112:1619-22.

Stevens SM, Lambert PR, Baker AB, Meyer TA. Malignant otitis externa: A novel stratification protocol for predicting treatment outcomes. Otol Neurotol. 2015;36(9):1492-8.






Original Research Articles